The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology

URL:  http://boards.fool.com/a-couple-of-upgrades-a-rec-from-cramer-and-vrtx-30027587.aspx

Subject:  Re: VRTX spiking in pre market Date:  5/8/2012  4:41 PM
Author:  PuddinHead42 Number:  24840 of 24974

a couple of upgrades, a rec from Cramer and VRTX is up to $64 at the close today. Guess I sold too soon. Still have half.

Fast money in the first day, slow money in day 2, dumb money in day 3 and fast money out. We will see.

People throwing around $4B in sales for the CF drug. It is expected to address 30% of the $70k worldwide cases (=21k patients). Except $200k to $350k for a year of treatment. So, of the 21,000 spread out over the world, how many have insurance that will pay $200k or $350k per year. Sure Europe has socialized medicine, but something like this seems pretty high - I bet you will need to get on a 2 year waiting list before they start shelling out. Love the company, but not sure about the true potential of this drug relative to $4B/year.
Copyright 1996-2014 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us